読み込み中
Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme. Ibezapolstat has successfully completed Phase II clinical trials for addressing Clostridium difficile infections. Additionally, Acurx is progressing with ACX-375C, an investigational therapeutic suitable for both oral and injectable administration. This compound is being developed to combat various gram-positive bacteria, including resistant strains such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and penicillin-resistant Streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was established in 2017 and is headquartered in Staten Island, New York.
前日終値
$1.25
−$0.05 · -3.85%
時間外
$1.28
+$0.03 · +2.40%
10月8日 19:16 ET
日中の時刻はETです。市場データは遅延する場合があります。
Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme. Ibezapolstat has successfully completed Phase II clinical trials for addressing Clostridium difficile infections. Additionally, Acurx is progressing with ACX-375C, an investigational therapeutic suitable for both oral and injectable administration. This compound is being developed to combat various gram-positive bacteria, including resistant strains such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and penicillin-resistant Streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was established in 2017 and is headquartered in Staten Island, New York.
日中レンジ
現在 $1.25
52週レンジ
現在 $1.25
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
49
適正価値
センチメント
54
まちまち
リスク
66
高リスク
モメンタム
19
強い下落
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme. Ibezapolstat has successfully completed Phase II clinical trials for addressing Clostridium difficile infections. Additionally, Acurx is progressing with ACX-375C, an investigational therapeutic suitable for both oral and injectable administration. This compound is being developed to combat various gram-positive bacteria, including resistant strains such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and penicillin-resistant Streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was established in 2017 and is headquartered in Staten Island, New York.
日中レンジ
現在 $1.25
52週レンジ
現在 $1.25
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 研究開発 | 18.35億 USD | 540.38万 USD | 604.36万 USD | 475.43万 USD | 203.02万 USD |
| 販売・一般管理 | 62.57億 USD | 869.93万 USD | 853.42万 USD | 733.85万 USD | 1078.4万 USD |
| 営業費用 | 809.2万 USD | 1410.31万 USD | 1457.78万 USD | 1209.28万 USD | 1281.42万 USD |
| 受取利息 | 12.54万 USD | — | — | — | — |
| 減価償却費と償却費 | — | 1412.32万 USD | — | — | — |
| 営業利益 | −809.2万 USD | −1410.31万 USD | −1457.78万 USD | −1209.28万 USD | −1281.42万 USD |
| 純利益 | −796.65万 USD | −1410.31万 USD | −1457.78万 USD | −1209.28万 USD | −1274.77万 USD |
会社概要が更新されました 2026年10月9日.
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
評価サンプルは3件と限定的です
この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
